Aurinia Pharmaceuticals (NASDAQ:AUPH) Lowered to Buy Rating by StockNews.com

StockNews.com downgraded shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a strong-buy rating to a buy rating in a report published on Monday morning.

Aurinia Pharmaceuticals Trading Down 0.5 %

Shares of Aurinia Pharmaceuticals stock opened at $7.97 on Monday. The firm has a market capitalization of $1.14 billion, a price-to-earnings ratio of -53.13 and a beta of 1.22. Aurinia Pharmaceuticals has a fifty-two week low of $4.71 and a fifty-two week high of $10.67. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The stock has a 50 day moving average of $8.60 and a 200 day moving average of $7.57.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Cibc World Markets Corp purchased a new position in Aurinia Pharmaceuticals in the fourth quarter worth approximately $113,000. Connor Clark & Lunn Investment Management Ltd. grew its position in Aurinia Pharmaceuticals by 22.5% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 556,454 shares of the biotechnology company’s stock worth $4,997,000 after acquiring an additional 102,195 shares during the period. Raymond James Financial Inc. acquired a new position in Aurinia Pharmaceuticals during the fourth quarter worth $215,000. SBI Securities Co. Ltd. acquired a new position in Aurinia Pharmaceuticals during the fourth quarter worth $25,000. Finally, Bailard Inc. acquired a new position in Aurinia Pharmaceuticals during the fourth quarter worth $128,000. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.